Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01673269 · ClinicalTrials.gov registry record · NA
Prospective Study of the Risk of Bacteremia in Directed Cholangioscopic Examination of the CBD
A NA study, sponsored by Texas Tech University Health Sciences Center, El Paso.
- Completed
- Registry status
- NA
- Development phase
- 60
- Enrollment target
NCT01673269 is a NA study that has completed, run by Texas Tech University Health Sciences Center, El Paso. The registered enrollment target is 60 participants.
The verdict
NCT01673269, a NA study, has completed, sponsored by Texas Tech University Health Sciences Center, El Paso.
- COMPLETED
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
Study Summary
When a doctor performs Endoscopic retrograde cholangiopancreatography "ERCP" (Endoscopy to examine the bile duct) a flexible tube is inserted into the mouth and into the stomach. The tube passes beyond the stomach and into an opening in the liver called the bile duct. Another small flexible endoscope is inserted inside the ERCP scope to directly visualize the bile duct to ensure that there are no cancers or stones in the bile duct and occasionally to take a sample from the bile duct. The purpose of our study is to examine wither performing this procedure can transmit bacteria from the bile duct to the main blood stream.
Interventions
- OTHER Blood culture ( aerobic and anaerobic)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2012-07 |
| Est. Completion | 2013-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01673269
The ClinicalTrials.gov registry entry for NCT01673269 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Texas Tech University Health Sciences Center, El Paso, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Blood culture ( aerobic and anaerobic) is the first listed.
NCT01673269 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01673269 about?
NCT01673269 is a clinical study titled "Prospective Study of the Risk of Bacteremia in Directed Cholangioscopic Examination of the CBD". When a doctor performs Endoscopic retrograde cholangiopancreatography "ERCP" (Endoscopy to examine the bile duct) a flexible tube is inserted into the mouth and into the stomach. The tube passes beyond the stomach and into an opening in the liver called the bile duct. Another small flexible endoscop...
What is the current status of trial NCT01673269?
This trial is currently completed. It is a NA study. The enrollment target is 60 participants. The study started on 2012-07. Estimated completion is 2013-10.
What interventions are being tested in trial NCT01673269?
The interventions under investigation include: Blood culture ( aerobic and anaerobic) (OTHER).
Who is sponsoring clinical trial NCT01673269?
This trial is sponsored by Texas Tech University Health Sciences Center, El Paso, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.